{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/psychosis-schizophrenia/prescribing-information/available-antipsychotics/","result":{"pageContext":{"chapter":{"id":"f78f8497-f98b-5445-82fe-23a4ced38576","slug":"available-antipsychotics","fullItemName":"Available antipsychotics","depth":2,"htmlHeader":"<!-- begin field 1ea56a36-a078-48fb-9da1-d63e996f77d5 --><h2>Available antipsychotics</h2><!-- end field 1ea56a36-a078-48fb-9da1-d63e996f77d5 -->","summary":"","htmlStringContent":"<!-- begin item cda58649-7c00-4305-b02a-6037983cf587 --><!-- begin field 64455a56-01e5-4563-863d-2ddd980b05e8 --><ul><li>Antipsychotics are available as oral preparations or depot injections. They are classified as first-generation antipsychotics (typical) and second-generation antipsychotics (atypical). For more information, see Table 1.</li><li>First-generation antipsychotics are thought to primarily exert their effects by blocking dopamine-2 receptors in the brain, whereas second-generation antipsychotics act on a range of receptors. Antipsychotics have significant effects on acetylcholine, histamine, norepinephrine, and serotonin pathway and can cause extrapyramidal symptoms (EPS) and a wide range of other <a class=\"topic-reference internal-reference\" href=\"/topics/psychosis-schizophrenia/prescribing-information/adverse-effects/\">adverse effects</a>.</li><li>In general, second-generation antipsychotics are associated with fewer EPS than first-generation antipsychotics. However, second-generation antipsychotics are associated with several other important adverse effects, such as weight gain, glucose intolerance, and hyperprolactinaemia.</li><li>There is no first-line antipsychotic drug suitable for all people with psychosis, and (except for clozapine) little meaningful difference in efficacy. Choice, therefore, depends on the person's personal choice, medication history, degree of sedation required, risk of particular <a class=\"topic-reference internal-reference\" href=\"/topics/psychosis-schizophrenia/prescribing-information/adverse-effects/\">adverse effects</a>, and the degree of <a class=\"topic-reference internal-reference\" href=\"/topics/psychosis-schizophrenia/background-information/definition/\">negative symptoms</a> (second-generation antipsychotics may be more likely to improve negative symptoms).</li><li>Clozapine is generally offered to people who do not respond adequately to two other antipsychotics and is always initiated and monitored in secondary care.</li><li>Individual responses to antipsychotics are variable. Dosage and dosage interval will, therefore, be adjusted specifically according to the person's response. <strong>CKS recommends that people requiring a change in the dose of their antipsychotic should be referred to specialist mental health services, or that specialist advice should be sought.</strong></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/psychosis-schizophrenia/references/\">NICE, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/psychosis-schizophrenia/references/\">Joint Formulary Committee, 2020</a>]</p><p><strong>Table 1.</strong> Antipsychotics available to prescribe.</p><table><thead><tr><th scope=\"col\">Oral first-generation (typical)</th><th scope=\"col\">Oral second-generation (atypical)</th><th scope=\"col\">Antipsychotic depot injections*</th></tr></thead><tbody><tr><td><p>Benperidol</p><p>Chlorpromazine</p><p>Flupentixol</p><p>Haloperidol</p><p>Levomepromazine</p><p>Pericyazine</p><p>Perphenazine</p><p>Pimozide</p><p>Prochlorperazine</p><p>Promazine</p><p>Sulpiride</p><p>Trifluoperazine</p><p>Zuclopenthixol</p></td><td><p>Amisulpride</p><p>Aripiprazole</p><p>Clozapine</p><p>Olanzapine</p><p>Paliperidone</p><p>Quetiapine</p><p>Risperidone</p></td><td><p>Aripiprazole</p><p>Flupentixol decanoate</p><p>Fluphenazine decanoate</p><p>Haloperidol</p><p>Olanzapine embonate</p><p>Paliperidone</p><p>Pipotiazine palmitate</p><p>Risperidone</p><p>Zuclopenthixol decanoate</p></td></tr><tr><td colspan=\"3\">* Antipsychotic depot injections are used for maintenance therapy when adherence to oral treatment is unreliable. They are administered every 1–4 weeks.</td></tr><tr><td colspan=\"3\"><strong>Data from: </strong>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/psychosis-schizophrenia/references/\">Joint Formulary Committee, 2020</a>]</td></tr></tbody></table><!-- end field 64455a56-01e5-4563-863d-2ddd980b05e8 --><!-- end item cda58649-7c00-4305-b02a-6037983cf587 -->","topic":{"id":"9b90da89-2ffd-5b6a-9fc6-ea342404d5d8","topicId":"fd02ebc3-0f02-42b5-8737-e0608ca4330d","topicName":"Psychosis and schizophrenia","slug":"psychosis-schizophrenia","lastRevised":"Last revised in November 2020","chapters":[{"id":"d60310a0-752b-5399-8488-a567bf6a3925","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"10869ad6-510d-54db-bc6a-ce3618a1c478","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"1025e31f-c89d-5344-b4ae-d5e8950a5c0e","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"594160f5-1a9b-56f0-952c-5c400ea28785","slug":"changes","fullItemName":"Changes"},{"id":"e20c0ce8-30f6-5e09-81d1-3e6005f85efe","slug":"update","fullItemName":"Update"}]},{"id":"4c4f0990-85fa-5fc4-9a58-9f02a868a971","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"02637a5f-4552-5e73-9245-cf480497e9a5","slug":"goals","fullItemName":"Goals"},{"id":"8c88de52-9655-52d8-b302-67641ae05beb","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"c6754da2-fd29-5d45-8097-40b8ec0589cd","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"31a210b8-403b-5530-b1ea-0b44a2595f07","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"c5630117-b04c-558a-b516-41c3eab9adbd","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"e9e078fd-a616-51bf-944f-2efbb2a01feb","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"99d1cff5-adca-5573-9fa8-58c2e9f937e0","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"23ac3781-557a-57b8-95b5-83db37a53fda","slug":"definition","fullItemName":"Definition"},{"id":"3e7238cc-23d8-56f6-a8af-255ed6a876d7","slug":"causes-risk-factors","fullItemName":"Causes and risk factors"},{"id":"9576e7c9-3a1e-57d3-bb86-a4e5e10462e1","slug":"prevalence","fullItemName":"Prevalence"},{"id":"b79b29b0-d7ad-5bad-87fd-e5a48ced5427","slug":"course-prognosis","fullItemName":"Course and prognosis"},{"id":"598444d7-6337-5133-a088-176b1f83ab01","slug":"complications","fullItemName":"Complications"}]},{"id":"a913b80f-eec4-5c47-9d9c-0b20f4648b73","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"e7897095-2be8-5df7-a7e3-c1060d4a453a","slug":"identifying-someone-at-risk-of-a-psychotic-disorder-or-experiencing-their-first-episode-of-psychosis","fullItemName":"Identifying someone at risk of a psychotic disorder or experiencing their first episode of psychosis"},{"id":"a8f36210-9cb6-590b-8e3d-7ddbc6d31e88","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"f86ff69c-c33e-5b8c-affa-04759f25bf5a","fullItemName":"Management","slug":"management","subChapters":[{"id":"34c0807e-9463-536b-9ff4-c3537046a6ba","slug":"primary-care-management","fullItemName":"Scenario: Primary care management"},{"id":"468f8b6f-bc79-5ecd-b1c2-d7ff27721abe","slug":"managing-relapse","fullItemName":"Scenario: Managing relapse"},{"id":"30f16f24-0127-53b7-bd08-c679a189090b","slug":"the-routine-schizophrenia-or-psychosis-review","fullItemName":"Scenario: The routine schizophrenia or psychosis review"},{"id":"c20919b9-2e4c-5c56-b3cd-7fb432199a8b","slug":"women-of-childbearing-age","fullItemName":"Scenario: Women of childbearing age"}]},{"id":"a9fe56bb-7ae3-5523-b0e2-5b7da5aa8439","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"f78f8497-f98b-5445-82fe-23a4ced38576","slug":"available-antipsychotics","fullItemName":"Available antipsychotics"},{"id":"05e42d64-ee5a-5c2b-8817-5fc77abb19ec","slug":"adverse-effects","fullItemName":"Adverse effects"},{"id":"25b3e7d5-bc3d-5749-9304-a717c1f4e386","slug":"interactions","fullItemName":"Interactions"},{"id":"ed339043-f5e2-5209-9ba0-cb06890e1050","slug":"monitoring","fullItemName":"Monitoring"}]},{"id":"7ae82132-000d-507c-b73d-542c43656041","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"1bf0a6af-76cf-5f6b-b7fb-4c746ff0f413","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"49b46ed4-7209-5c01-b07f-54117f9ad3c0","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"a4647644-8726-5bfc-b471-6e157c3f10a3","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"a31ae673-4520-58d5-95ee-db2395fb5238","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"3beebe4c-a826-5b46-a8cd-a97fe8ec3b8b","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"aaaadecf-036b-531f-a8bf-75fccd84219f","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"49078833-deae-54f3-ad89-562370e4d181","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"a9fe56bb-7ae3-5523-b0e2-5b7da5aa8439","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[]}}},"staticQueryHashes":["3666801979"]}